Intranasal Mometasone Does Not Cause Hypertension
Intranasal mometasone furoate does not cause high blood pressure in otherwise healthy adults; in fact, it may actually lower blood pressure by relieving nasal congestion and improving oxygenation. 1
Evidence That Mometasone Lowers—Not Raises—Blood Pressure
The most relevant clinical study directly addressing this question found that 4 weeks of intranasal mometasone therapy significantly decreased daytime systolic blood pressure (120 vs. 117 mmHg, p=0.024), diastolic blood pressure (73 vs. 71 mmHg, p=0.027), and mean arterial pressure (86 vs. 83 mmHg, p=0.007) in 45 patients with allergic rhinitis. 1 This blood pressure reduction occurs because severe nasal congestion causes hypoxia and sympathetic nervous system activation, which elevates blood pressure; treating the congestion with mometasone reverses this mechanism. 1
Systemic Safety Profile of Intranasal Mometasone
Intranasal mometasone has negligible systemic absorption (approximately 1% bioavailability) and does not reach clinically significant blood concentrations. 2, 3 This minimal systemic exposure is due to the drug's inherently low aqueous solubility—only a small fraction crosses the nasal mucosa into the bloodstream—and extensive first-pass hepatic metabolism of any swallowed drug. 2
Multiple pharmacokinetic studies in both adults and children confirm that systemic exposure to mometasone after intranasal administration is negligible, with no clinically significant suppression of the hypothalamic-pituitary-adrenal axis at standard doses (100-200 mcg/day). 2, 4 The drug has been rigorously assessed in approximately 4,500 patients in clinical trials, with epistaxis, headache, and pharyngitis being the most common adverse effects—not cardiovascular effects. 2
Guideline Perspective on Intranasal Corticosteroids and Blood Pressure
Major allergy and rhinology guidelines explicitly state that intranasal corticosteroids, when given at recommended doses, are not generally associated with clinically significant systemic side effects, including cardiovascular effects. 5 This stands in stark contrast to oral decongestants (pseudoephedrine, phenylephrine), which do cause blood pressure elevation through systemic vasoconstriction, though this is rarely noted in normotensive patients and only occasionally in those with controlled hypertension. 5, 6
The guidelines emphasize that hypertensive patients taking oral decongestants should be monitored for blood pressure changes, but no such monitoring recommendation exists for intranasal corticosteroids like mometasone. 5
Important Clinical Distinctions
Intranasal mometasone reduces vascular permeability and decreases blood vessel density in nasal mucosa through its anti-inflammatory effects, which is fundamentally different from the vasoconstriction caused by decongestants. 7
The drug's glucocorticoid anti-inflammatory effect has minimal systemic activity, as confirmed by in vitro experiments showing inhibition of pro-inflammatory Th2 cytokines without systemic corticosteroid exposure. 7
Long-term safety data extending up to 52 weeks of continuous use show no systemic adverse effects, including no impact on blood pressure, bone density, or ocular complications. 4
Common Pitfall to Avoid
Do not confuse intranasal corticosteroids with oral or topical nasal decongestants—only decongestants (not intranasal steroids) carry a risk of blood pressure elevation. 5, 6 Patients with hypertension can safely use intranasal mometasone without blood pressure monitoring, whereas oral decongestants require caution and monitoring in this population. 5